Publications by authors named "S Cigarran"
Article Synopsis
- * Aimed at improving prevention and treatment, this concept encourages a collaborative, lifelong strategy for risk assessment and early intervention, utilizing a new cardiovascular risk stratification equation starting at age 30.
- * In Spain, there is a call to adapt these insights into practice by enhancing teamwork among healthcare providers and creating multidisciplinary units to better manage CKM syndrome through a patient-focused perspective.
Article Synopsis
- Gut dysbiosis in chronic kidney disease (CKD) has been linked to anemia due to factors like increased uremic toxins, inflammation from gut barrier issues, and reduced production of beneficial short-chain fatty acids (SCFAs).
- Addressing gut dysbiosis can help manage anemia in CKD patients by reducing harmful medications, incorporating dietary changes, and using prebiotics or probiotics to enhance beneficial gut bacteria.
- Improving gut health in CKD not only alleviates anemia symptoms but can also boost the effectiveness of treatments like erythropoiesis-stimulating agents (ESAs) in patients unresponsive to standard therapies.
Article Synopsis
- Intradialytic parenteral nutrition (IDPN) is an effective nutritional strategy for malnourished patients on hemodialysis, especially those who haven’t responded well to standard dietary methods.
- Current guidelines for IDPN lack practical implementation strategies, which has limited its usage in clinical settings.
- This review offers a comprehensive roadmap covering when to start IDPN, what nutrients to include, administration methods, monitoring effectiveness, and conditions for discontinuation to enhance nutritional care for hemodialysis patients.
Sarcopenia and dynapenia are two terms associated with ageing that respectively define the loss of muscle mass and strength. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) introduced the EWGSOP2 diagnostic algorithm for sarcopenia, which integrates both concepts. It consists of 4 sequential steps: screening for sarcopenia, examination of muscle strength, assessment of muscle mass and physical performance; depending on these last 3 aspects sarcopenia is categorised as probable, confirmed, and severe respectively.
View Article and Find Full Text PDFSodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was early appearent that these drugs increased erythropoietin levels and erythropoiesis, and improved iron metabolism. Mediation studies found that the increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs.
View Article and Find Full Text PDF